Date Updated
EB Type
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Name of Company
Stanford University
Recruitment Status
About the Study

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

Trial Entry Criteria
  • Clinical diagnosis of RDEB by local dermatologist
  • 7 years of age or older
  • Visit for exclusion criteria.


Contacts & Location

If you have any questions or are interested in participating in this clinical trial, please contact:

Irene Bailey-Healy


Stanford University School of Medicine
Stanford, California, United States, 9430

Get more information on

Back to main Clinical Trials listing